Assertio Holdings Inc (ASRT)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$23.500.00%
Close 2026-06-17 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Assertio is improving cash flow from operations, rising from negative $29.97M to positive $8.56M in 2026-Q1. The company is pursuing strategic acquisitions to grow its market position. Analysts expect revenue growth of about 15% next year. The recent acquisition by Zydus supports growth ambitions.
Assertio remains loss-making with negative EPS expected for 2026. Management is volatile and the company faces regulatory and legal challenges. The stock price is deeply discounted, reflecting elevated risk and uncertain recovery.
The market prices Assertio about 60% below our fair value, reflecting skepticism about its turnaround. Analysts expect 15% revenue growth, but implied earnings growth is negative over 3 to 5 years. Our fair value is well above the Street median, indicating a more optimistic view.
Breaks if: No progress or deterioration in capital allocation strategies within next 4 quarters
Optimize capital allocation to improve financial stability and shareholder value.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds to the uncertainty in its long-term prospects.
The market appears to have priced in a low expectations gap, suggesting that ASRT is seen as cheap compared to its peers. However, the valuation is justified given the company's current challenges and recent performance.
Fundamentally, ASRT has shown some improvement in cash flow from operations, moving from a significant loss to a positive figure. However, the company remains loss-making overall, indicating that further operational improvements are necessary.
The thesis hinges on the performance of sector bellwethers like TEVA, HLN, and ZTS. If these companies continue to perform well, it could provide a favorable environment for ASRT. Conversely, any negative guidance or performance from these peers could adversely affect ASRT's prospects.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: cash from operations falls below $8.56M in any quarter after 2026-Q1
Enhance operational efficiency to generate positive cash flow.
Stated in 2 of last 2 quarters. Cash from operations improved significantly from negative $29.97M in 2025-Q4 to $8.56M in 2026-Q1, indicating progress in operational efficiency. However, net income remains negative, suggesting further improvement is needed.
“Cash from operations improved to $8.56M.”
“Cash from operations was negative $29.97M.”
Breaks if: Revenue growth falls below 15% YoY in any quarter after 2026-Q2
Focus on acquiring companies to enhance growth and market position.
Breaks if: No strategic acquisitions completed or announced within next 4 quarters
Focus on acquiring companies to enhance growth and market position.
In the next 1 to 3 years, ASRT's outlook remains uncertain, influenced by both sector dynamics and its internal operational improvements. Not investment advice.